Contact your GP or prescribing clinician if you experience : Severe or worsening fatigue that significantly impairs daily activities or persists beyond several weeks of treatment Extreme weakness or inability to perform usual tasks Dizziness or fainting , particularly on standing, which may indicate dehydration or blood pressure changes Persistent nausea or vomiting preventing adequate food or fluid intake Signs of dehydration : dark urine, reduced urination, dry mouth, confusion Chest pain, palpitations, or breathlessness accompanying tiredness Mood changes , including low mood or depression, which can manifest as fatigue Right upper abdominal pain, fever or yellowing of the skin/eyes , which could indicate gallbladder problems (GLP-1 medications may increase gallstone risk) For urgent but non-emergency concerns, you can contact NHS 111 for advice
Headaches are more likely and more severe
Along with the peak power of the electric motor, this defines the acceleration performance (0-60 mph time) of the vehicle
Participant characteristics Both participant arms were well balanced on all characteristics, though the intervention arm contained a slightly greater proportion of females than the placebo arm (33.7% female vs 25.0% female, respectively
The 833 patent was filed on May 17, 2006, and was granted on February 14, 2012
The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms
